Date：29 July (Friday) 12:30 – 13:50 (GMT+8)
Venue：701EF, TaiNEX2, Taipei + Online event platform
With more than 2,200 treatments currently under clinical development, the pipeline of cell and gene therapies (CGT) is expanding at an astonishing rate. A record US$23 billion flowed into gene and cell therapy developers in 2021, according to the Alliance for Regenerative Medicine. Continuing advances in these technologies promise to treat and potentially cure not only rare diseases but also more prevalent conditions. Taiwan is well placed to benefit from joining Japan in adopting regulations friendly to the CGT industry. However, significant challenges remain around safety, manufacturing (often on an individualized patient basis), quality control, and managing the complexity of living cell supply chains. Join our panel of experts in this luncheon session as they present emerging advances in CGT both in Asia and globally, new T-cell and CART-T applications, cell storage and manufacturing issues, regulatory developments and more.